Moreover, therapies aimed at counteracting the effects of cancer-associated BRAF mutations may provide a tailored approach to inhibit oncogenic signaling, offering new opportunities for more effective treatments in cancers with SPOP or BRAF mutations, such as endometrial and PCa. Here, BRAF is linked to posterior cortical atrophy.